Nuclear Medicine, Oncology and Radiotherapy Institute

NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer

Retrieved on: 
Tuesday, June 14, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, PD-L1, BOR, CA, Baylor University, National Cancer Institute, TNBC, Biotechnology, Safety, ORR, Toxicity, Plasma, Inflammation, Breast cancer, Cancer, NIH, VEGF, Dialysis, Financial toxicity, Baylor College of Medicine, Multimedia, National Institutes of Health, FDA, Therapy, Patient, Risk, Technology, National, CE marking, Clinical trial, NCI, IL-6, PFS, RECIST, Nuclear Medicine, Oncology and Radiotherapy Institute, Pharmaceutical industry, Medical imaging, Vaccine, Column

View the full release here: https://www.businesswire.com/news/home/20220614005928/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220614005928/en/
    Immunicom's LW-02 molecular ligand-capture column (Photo: Business Wire)
    We are honored to receive this grant from the NCI/NIH recognizing the potential of Immunopheresis therapy.
  • This clinical trial is a monumental step for Immunicom to address unmet needs for patients with difficult-to-treat cancers, said Principal Investigator Dr. Robert Segal, Immunicoms Chief Medical Officer.
  • In a process like dialysis, Immunopheresis therapy removes sTNF-R1/2 from plasma, helping kickstart endogenous TNF- response to cancer without toxicities that increase the risk of side effects.
  • Immunicom is headquartered in San Diego, CA, with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.

Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors

Retrieved on: 
Monday, October 25, 2021
Amos, TEL, MD, Cancer, Radiation, Radiation therapy, University, LinkedIn, Medical degree, Hematology, College, American Board of Radiology, Colorectal cancer, Independent director, Board of directors, Nuclear Medicine, Oncology and Radiotherapy Institute, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Security (finance), Ministry of Health (Malaysia), Policy, Ministry, ABR, Government, Central Waqf Council, OTCQB, Time, Company, Instagram, Board, OTC, University of Illinois College of Medicine, Exchange, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Report, American Board of Commissioners for Foreign Missions, Pharmaceutical industry, Medical device

Dr. Tova specializes in treating cancer with radiation, using radiation therapy to treat a wide variety of cancers.

Key Points: 
  • Dr. Tova specializes in treating cancer with radiation, using radiation therapy to treat a wide variety of cancers.
  • Dr. Tova is certified by the American Board of Radiology (ABR), and currently serves as Director of the Radiotherapy Institute at Ziv Hospital in Israel.
  • Company Director and Head of Advisory Board, Dr. Gil Feiler, commented: "It is with great pleasure that I welcome Dr. Yonina Tova to our Advisory Board.
  • For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.